Selective orexin 2 receptor agonist TAK-925 to treat narcolepsy: results of a randomized, double-blind, placebo-controlled, multiple-ascending-dose, phase 1 study in patients with narcolepsy type 2

被引：0

作者：

Tanaka, S. -I. ^{[1
]}

Evans, R. ^{[2
]}

Alexander, R. ^{[2
]}

Imazaki, M. ^{[1
]}

Touno, S. ^{[1
]}

Shimizu, K. ^{[1
]}

Wu, J. ^{[2
]}

Faessel, H. ^{[2
]}

Ratti, E. ^{[2
]}

Hartman, D. ^{[1
]}

机构：

[1] Takeda Pharmaceut Co Ltd, Takeda Dev Ctr Japan, Osaka, Japan

[2] Takeda Pharmaceut Int Co, Neurosci Therapeut Area Unit, Cambridge, MA USA

来源：

JOURNAL OF SLEEP RESEARCH | 2020年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P206

引用

页码：171 / 172

页数：2

共 50 条

[41] Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled multiple-ascending-dose study
Li, Lijun
Gao, Hongzhi
Lou, Kun
Luo, Hongmei
Hao, Sheng
Yuan, Jing
Liu, Zeyuan
Dong, Ruihua
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (05): : 2017 - 2024
[42] Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies
Kuter, David J.
Allen, Lee F.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (03) : 466 - 478
[43] Nebivolol in the treatment of patients with stage 1 and stage 2 hypertension: Results of a randomized, double-blind, placebo-controlled study
Weiss, RJ
Weber, MA
Carr, AA
Riggs, BS
AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 96A - 96A
[44] Effects of an orexin receptor 2-selective agonist on blood pressure nocturnal dipping profile in patients with narcolepsy type 1
Karas, Marta
Onorati, Francesco
Tracey, Brian
Cai, Alice
Barateau, Lucie
Dauvilliers, Yves
Volfson, Dmitri
JOURNAL OF SLEEP RESEARCH, 2024, 33
[45] Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial
Hartemann, Agnes
Bensimon, Gilbert
Payan, Christine A.
Jacqueminet, Sophie
Bourron, Olivier
Nicolas, Nathalie
Fonfrede, Michele
Rosenzwajg, Michelle
Bernard, Claude
Klatzmann, David
LANCET DIABETES & ENDOCRINOLOGY, 2013, 1 (04): : 295 - 305
[46] Phase I, Randomized, Double-Blind, Placebo-Controlled, Multiple Intravenous, Dose-Ascending Study of Sirukumab in Cutaneous or Systemic Lupus Erythematosus
Szepietowski, Jacek C.
Nilganuwong, Surasak
Wozniacka, Anna
Kuhn, Annegret
Nyberg, Filippa
van Vollenhoven, Ronald F.
Bengtsson, Anders A.
Reich, Adam
de Vries, Dick E.
van Hartingsveldt, Bart
Robinson, Donald W., Jr.
Gordon, Robert
Hsu, Benjamin
ARTHRITIS AND RHEUMATISM, 2013, 65 (10): : 2661 - 2671
[47] RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED DOSE-ESCALATION PHASE 1 STUDY OF AEROSOLIZED PIRFENIDONE
Khoo, J.
Montgomery, B.
Otto, K.
Surber, M.
Glaspole, I
RESPIROLOGY, 2019, 24 : 177 - 177
[48] Efficacy and Safety of AMG 853 in Asthma: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Busse, W. W.
Wenzel, S. E.
Meltzer, E. O.
Kerwin, E. M.
Liu, M. C.
Zhang, N.
Chon, Y.
Lin, J.
Lin, S.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB202 - AB202
[49] Fontolizumab in Moderate to Severe Crohn's Disease: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study
Reinisch, Walter
de Villiers, Williem
Bene, Laszlo
Simon, Laszlo
Racz, Istvan
Katz, Seymour
Altorjay, Istvan
Feagan, Brian
Riff, Dennis
Bernstein, Charles N.
Hommes, Daniel
Rutgeerts, Paul
Cortot, Antoine
Gaspari, Michael
Cheng, May
Pearce, Tillman
Sands, Bruce E.
INFLAMMATORY BOWEL DISEASES, 2010, 16 (02) : 233 - 242
[50] Results from PIONEER: a randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis
Radia, Deepti H.
Sabato, Vito
Castells, Mariana
Akin, Cem
Elberink, Hanneke Oude
Tashi, Tsewang
George, Tracy I.
Roche, Maria
DeAngelo, Daniel J.
Gotlib, Jason
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 8 - 9

← 1 2 3 4 5 →